PURPOSE: The objective of this study was to investigate the effects of polymer type and storage relative humidity (RH) on the crystallization kinetics of felodipine from amorphous solid dispersions. METHODS: Crystallization of the model drug felodipine from amorphous solid dispersion samples containing poly(vinyl pyrrolidone) (PVP) and hypromellose acetate succinate (HPMCAS) were evaluated. Samples at three different drug-polymer weight ratios (10, 25, and 50 wt. % polymer) were prepared and stored at six different RHs (0%, 32%, 52% or 66%, 75%, 86%, and 93%). Periodically, the fraction of the drug that had crystallized from the samples was quantified using powder X-ray diffractometry (PXRD). RESULTS: Felodipine crystallization rates from PVP-containing dispersions were found to be very sensitive to changes in storage RH, while crystallization rates from HPMCAS-containing dispersions were not. PVP and HPMCAS were similar in terms of their ability to inhibit crystallization at low RH, but when the storage RH was increased to 75% or above, felodipine crystallization from PVP-containing solid dispersions proceeded much faster. It is hypothesized that this trend was caused by moisture-induced drug-polymer immiscibility in PVP-felodipine system. For PVP-containing solid dispersion samples stored at 75% RH and above, crystallization of the model drug felodipine seemed to approach a kinetic plateau, whereby a fraction of the drug still remained amorphous even after storage for 500 days or more. CONCLUSIONS: The physical stability of solid dispersions as a function of RH is highly dependent on the polymer used to form the solid dispersion, with PVP-containing dispersions being much less physically stable at high RH than HPMCAS-containing dispersions.
PURPOSE: The objective of this study was to investigate the effects of polymer type and storage relative humidity (RH) on the crystallization kinetics of felodipine from amorphous solid dispersions. METHODS: Crystallization of the model drug felodipine from amorphous solid dispersion samples containing poly(vinyl pyrrolidone) (PVP) and hypromellose acetate succinate (HPMCAS) were evaluated. Samples at three different drug-polymer weight ratios (10, 25, and 50 wt. % polymer) were prepared and stored at six different RHs (0%, 32%, 52% or 66%, 75%, 86%, and 93%). Periodically, the fraction of the drug that had crystallized from the samples was quantified using powder X-ray diffractometry (PXRD). RESULTS:Felodipine crystallization rates from PVP-containing dispersions were found to be very sensitive to changes in storage RH, while crystallization rates from HPMCAS-containing dispersions were not. PVP and HPMCAS were similar in terms of their ability to inhibit crystallization at low RH, but when the storage RH was increased to 75% or above, felodipine crystallization from PVP-containing solid dispersions proceeded much faster. It is hypothesized that this trend was caused by moisture-induced drug-polymer immiscibility in PVP-felodipine system. For PVP-containing solid dispersion samples stored at 75% RH and above, crystallization of the model drug felodipine seemed to approach a kinetic plateau, whereby a fraction of the drug still remained amorphous even after storage for 500 days or more. CONCLUSIONS: The physical stability of solid dispersions as a function of RH is highly dependent on the polymer used to form the solid dispersion, with PVP-containing dispersions being much less physically stable at high RH than HPMCAS-containing dispersions.
Authors: Patrick J Marsac; Alfred C F Rumondor; David E Nivens; Umesh S Kestur; Lia Stanciu; Lynne S Taylor Journal: J Pharm Sci Date: 2010-01 Impact factor: 3.534
Authors: Geert Verreck; Karel Six; Guy Van den Mooter; Lieven Baert; Jef Peeters; Marcus E Brewster Journal: Int J Pharm Date: 2003-01-30 Impact factor: 5.875
Authors: Hitesh S Purohit; James D Ormes; Sugandha Saboo; Yongchao Su; Matthew S Lamm; Amanda K P Mann; Lynne S Taylor Journal: Pharm Res Date: 2017-04-28 Impact factor: 4.200
Authors: Saad M Alshahrani; Wenli Lu; Jun-Bom Park; Joseph T Morott; Bader B Alsulays; Soumyajit Majumdar; Nigel Langley; Karl Kolter; Andreas Gryczke; Michael A Repka Journal: AAPS PharmSciTech Date: 2015-01-08 Impact factor: 3.246
Authors: Lindsay A Wegiel; Laura I Mosquera-Giraldo; Lisa J Mauer; Kevin J Edgar; Lynne S Taylor Journal: Pharm Res Date: 2015-05-15 Impact factor: 4.200
Authors: Mohamed K Ghorab; Scott J Toth; Garth J Simpson; Lisa J Mauer; Lynne S Taylor Journal: Pharm Dev Technol Date: 2013-03-12 Impact factor: 3.133